N. Sumiyoshi

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

H. Saka, M. Satouchi, K. Goto, 2019, Cancer medicine.

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.

M. Nishio, N. Yamamoto, T. Tamura, 2021, Annals of Oncology.

LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC

Teruhiko Yoshida, Y. Ohe, M. Nishio, 2020 .

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

Y. Ohe, H. Saka, M. Satouchi, 2017, ESMO Open.

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Y. Ohe, H. Saka, M. Satouchi, 2017, Cancer science.